IBM announced plans to enlist some of the company’s leading scientists and technologists to help medical practitioners and insurance companies provide high-quality, evidence-based care to patients. As part of this initiative, IBM is collaborating with clinicians in medical institutions and hiring medical doctors to work alongside its researchers to develop new technologies, scientific advancements, and business processes for healthcare and insurance providers.
Dedicating $100 million over the next three years, the initiative will draw on IBM's leadership in systems integration, services research, cloud computing, analytics and emerging scientific areas – such as nanomedicine and computational biology – to drive innovations that empower practitioners to focus their efforts on patient care.
More than 100 researchers across IBM’s nine worldwide research laboratories and its collaboratories in Melbourne, Australia, and Taipei, Taiwan, are contributing to these efforts. As part of this initiative, IBM expects to hire several physicians, clinicians, nurses, engineers, economists and social scientists. Additionally, the company will seek new research collaborations with businesses, governments and universities. IBM will focus its research on three main areas:
Evidence generation, which uses scientific methods to utilize health data to help develop effective treatment methodologies, and then deliver it in a context-dependant and personalized way at the point of care;  Improving service quality through simplifying the healthcare delivery process; and New incentives and models to shift the healthcare system to one that rewards based on patient outcomes rather than only treatment and volume of care.  Privacy and security of patient data and compliance with current healthcare regulations will be addressed throughout the new research initiative.
IBM researchers across the globe are collaborating on a variety of efforts to help bring more a more evidence-based approach to patient care.  Current research efforts include:
-Computer scientists are working with cardiologists to create a system that helps identify difficult-to-see patterns in symptoms and characteristics across a patient set that gives better insight into diagnoses and the comparative effectiveness of different treatments and outcomes. 
-Researchers are working with the European HYPERGENES consortium to understand the interrelations of genomic, clinical and environmental factors underlying essential hypertension (EH) and to help improve diagnostic accuracy and introduce new strategies for early detection, prevention and therapy for individuals that suffer from EH. Through attempting to build a comprehensive EH disease model based on biological pathways, they hope to identify new genetic variations contributing to EH and associated organ damage. 
-Chronic disease, patients taking multiple medications and aging populations across the globe present additional challenges and burdens on the healthcare system. Scientists and mathematicians across IBM are using data mining, information management and advanced analytics to build a system that could help better understand and address adverse drug reactions and interactions as well as provide insights to clinicians on effective courses of treatment. 
-In China, IBM and Peking University People’s Hospital are building an evidence-based clinical care solution that focuses on chronic disease management and integrates a comprehensive view of a patient's health data, best practices from previous diagnoses, treatment, research and more to provide doctors with clinical decision support at the point of care.  The solution also incorporates a mobile platform that will enable doctors and nurses to provide remote care and monitoring service. 
-Scientists are also combining their deep expertise in nanotechnology and biology to develop new applications for personalized medicine.  Scientists have begun to develop medical diagnostics tests of the future that can quickly and accurately analyze biological samples and test for a variety of diseases.  IBM is also collaborating with Roche to develop a nanopore-based technology that will be expected to read and sequence human DNA quickly and efficiently for more personalized diagnosis and treatment.  Improving Service Quality and New Incentive Models.